Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Fuji Pharma Co stock price, quote, forecast and news

4554.T
JP3816200004
938283

Price

1,466.00
Today +/-
+0
Today %
+0 %
P

Fuji Pharma Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Fuji Pharma Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Fuji Pharma Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Fuji Pharma Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Fuji Pharma Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Fuji Pharma Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Fuji Pharma Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Fuji Pharma Co’s growth potential.

Fuji Pharma Co Revenue, EBIT and net profit per share

DateFuji Pharma Co RevenueFuji Pharma Co EBITFuji Pharma Co Net Income
2027e51.42 B undefined0 undefined4.66 B undefined
2026e55.65 B undefined0 undefined4.49 B undefined
2025e51.66 B undefined0 undefined3.99 B undefined
2024e47.96 B undefined0 undefined5.8 B undefined
202340.89 B undefined3.86 B undefined3.44 B undefined
202235.43 B undefined3.78 B undefined2.7 B undefined
202133.99 B undefined3.35 B undefined2.43 B undefined
202033.79 B undefined3.14 B undefined2.09 B undefined
201936.28 B undefined4.17 B undefined2.96 B undefined
201837.91 B undefined4.39 B undefined3.37 B undefined
201735.39 B undefined4.31 B undefined3.3 B undefined
201634.23 B undefined3.57 B undefined2.12 B undefined
201531.68 B undefined3.25 B undefined2.09 B undefined
201429.22 B undefined3.17 B undefined2.08 B undefined
201325.17 B undefined3.26 B undefined2.07 B undefined
201221.52 B undefined2.75 B undefined1.37 B undefined
201121.62 B undefined3.57 B undefined2.21 B undefined
201019.7 B undefined3.23 B undefined1.94 B undefined
200917.2 B undefined2.41 B undefined1.53 B undefined
200814.94 B undefined2.01 B undefined1.25 B undefined
200713.25 B undefined2 B undefined1.19 B undefined
200611.24 B undefined1.47 B undefined916 M undefined
200510.13 B undefined960 M undefined562 M undefined
20049.7 B undefined1.4 B undefined844 M undefined

Fuji Pharma Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e
5.475.095.585.866.156.858.689.710.1311.2413.2514.9417.219.721.6221.5225.1729.2231.6834.2335.3937.9136.2833.7933.9935.4340.8947.9651.6655.6551.42
--7.099.714.955.0911.3826.6011.754.4810.9817.8812.7315.1414.539.78-0.4816.9816.058.448.053.387.13-4.30-6.850.584.2215.4217.297.727.73-7.61
54.6953.5953.7247.6951.1546.5944.4443.8144.2742.3544.0442.7044.7145.8647.4043.0943.4642.3840.9439.5541.5942.0743.5444.0143.4041.1040.39----
2.992.7332.793.153.193.864.254.484.765.846.387.699.0310.259.2710.9412.3812.9713.5414.7215.9515.814.8714.7514.5616.520000
0.810.570.850.560.840.781.251.40.961.4722.012.413.233.572.753.263.173.253.574.314.394.173.143.353.783.860000
14.8411.2715.279.6313.6211.3114.4014.449.4813.0915.0813.4514.0016.4116.4912.7612.9510.8610.2610.4212.1911.5811.509.299.8510.669.44----
0.510.340.650.430.520.590.790.840.560.921.191.251.531.942.211.372.072.082.092.123.33.372.962.092.432.73.445.83.994.494.66
--32.6791.76-33.5919.6314.2933.786.57-33.4162.9930.354.8621.8827.3913.43-37.8250.840.480.671.2455.852.15-12.16-29.6116.6410.8627.4168.73-31.1112.523.76
-------------------------------
-------------------------------
29292928272625242425262626262628283030.4229.9229.9329.9330.5331.1626.8724.2924.30000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Fuji Pharma Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Fuji Pharma Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Fuji Pharma Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Fuji Pharma Co's financial health and stability.

Assets

Fuji Pharma Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Fuji Pharma Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Fuji Pharma Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Fuji Pharma Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.780.891.041.421.410.91.451.992.032.473.163.52.333.333.233.113.154.534.473.962.923.373.724.4
0.260.270.280.340.340.430.580.590.80.951.031.021.211.411.652.081.922.022.252.132.062.112.753.02
000000000000000000000000
-0.6-0.79-1.24-1.26-0.94-1.15-1.36-1.09-1.84-1.71-2.35-2.79-2.64-1.38-2.12-4.54-1.07-3.26-3.381.031.010.02-6.95-4.95
40108462354516098173-38101339222270264-12-51505-53430-87-216497-175-556
000000000339861604458457053415982104
0.680.370.520.540.590.60.30.710.741.211.330.991.371.471.010.871.091.80.960.720.911.50.95
0.480.480.140.730.850.340.771.660.951.822.171.951.173.632.760.594.513.243.777.035.775.99-0.661.92
-309-439-2,131-703-998-1,323-2,666-532-1,806-1,746-1,701-2,702-1,652-3,326-2,021-1,543-2,654-1,542-1,630-3,284-2,615-3,896-12,423-3,897
3.870.09-1.36-0.6-0.79-1.34-2.36-0.09-1.33-1.86-1.4-2.290.08-6.6-1.981-3.32-1.53-1.07-12.02-2.62-2.35-11.27-5.24
4.180.530.770.10.21-0.010.30.440.47-0.110.30.411.73-3.280.052.54-0.670.010.56-8.74-01.551.15-1.34
000000000000000000000000
-0.06-0.010000000001.3-0.34.27-0.8-2.450.75-2.34-1.175.881.364.775.822.82
-0.16-0.23-0.24-0.73-001.3400001.65002.69-1.500-0.042.230-9.3900
-0.33-0.35-0.34-0.85-0.17-0.181.17-0.18-0.28-0.27-0.332.5-0.843.741.29-4.640.08-3.04-27.270.45-5.445.091.92
------------12.00--2.00--5.00-1.00-1.00-1.00-1.00-1.00-2.00-1.00-1.00
-107-104-105-123-167-178-172-180-283-270-334-437-535-522-593-675-674-704-794-839-904-807-729-899
4.020.21-1.56-0.74-0.1-1.18-0.431.38-0.66-0.310.432.160.420.842.16-3.021.15-1.310.752.243.55-1.84-6.65-1.22
173.935.6-1,995.626.9-144.8-985.8-1,899.61,126.6-853.570.3466.9-748.7-481.1305737-9521,8551,6962,1423,7503,1542,097-13,082-1,978
000000000000000000000000

Fuji Pharma Co stock margins

The Fuji Pharma Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fuji Pharma Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fuji Pharma Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Fuji Pharma Co's sales revenue. A higher gross margin percentage indicates that the Fuji Pharma Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Fuji Pharma Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Fuji Pharma Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Fuji Pharma Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Fuji Pharma Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Fuji Pharma Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Fuji Pharma Co Margin History

Fuji Pharma Co Gross marginFuji Pharma Co Profit marginFuji Pharma Co EBIT marginFuji Pharma Co Profit margin
2027e40.39 %0 %9.07 %
2026e40.39 %0 %8.07 %
2025e40.39 %0 %7.73 %
2024e40.39 %0 %12.09 %
202340.39 %9.44 %8.4 %
202241.1 %10.66 %7.61 %
202143.4 %9.85 %7.16 %
202044.01 %9.29 %6.17 %
201943.54 %11.5 %8.16 %
201842.07 %11.58 %8.89 %
201741.59 %12.19 %9.33 %
201639.55 %10.42 %6.19 %
201540.94 %10.26 %6.6 %
201442.38 %10.86 %7.11 %
201343.46 %12.95 %8.21 %
201243.09 %12.76 %6.37 %
201147.4 %16.49 %10.2 %
201045.86 %16.41 %9.87 %
200944.71 %14 %8.87 %
200842.7 %13.45 %8.38 %
200744.04 %15.08 %9.01 %
200642.35 %13.09 %8.15 %
200544.27 %9.48 %5.55 %
200443.81 %14.44 %8.71 %

Fuji Pharma Co Stock Sales Revenue, EBIT, Earnings per Share

The Fuji Pharma Co earnings per share therefore indicates how much revenue Fuji Pharma Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fuji Pharma Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fuji Pharma Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fuji Pharma Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fuji Pharma Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Fuji Pharma Co Revenue, EBIT and net profit per share

DateFuji Pharma Co Sales per ShareFuji Pharma Co EBIT per shareFuji Pharma Co Earnings per Share
2027e2,117.12 undefined0 undefined191.98 undefined
2026e2,291.53 undefined0 undefined185.03 undefined
2025e2,127.08 undefined0 undefined164.43 undefined
2024e1,974.61 undefined0 undefined238.66 undefined
20231,682.58 undefined158.76 undefined141.35 undefined
20221,458.27 undefined155.48 undefined110.98 undefined
20211,265.14 undefined124.65 undefined90.52 undefined
20201,084.59 undefined100.75 undefined66.92 undefined
20191,188.36 undefined136.69 undefined97.02 undefined
20181,266.64 undefined146.72 undefined112.67 undefined
20171,182.44 undefined144.15 undefined110.3 undefined
20161,144.18 undefined119.27 undefined70.8 undefined
20151,041.38 undefined106.87 undefined68.77 undefined
2014973.83 undefined105.77 undefined69.27 undefined
2013899.07 undefined116.46 undefined73.86 undefined
2012768.57 undefined98.11 undefined48.96 undefined
2011831.69 undefined137.12 undefined84.81 undefined
2010757.62 undefined124.35 undefined74.77 undefined
2009661.5 undefined92.62 undefined58.69 undefined
2008574.54 undefined77.27 undefined48.15 undefined
2007509.65 undefined76.85 undefined45.92 undefined
2006449.64 undefined58.84 undefined36.64 undefined
2005422.04 undefined40 undefined23.42 undefined
2004403.96 undefined58.33 undefined35.17 undefined

Fuji Pharma Co business model

Fuji Pharma Co Ltd is a Japanese company specializing in the healthcare industry. The company was founded in 2001 and is headquartered in Tokyo, Japan. It is listed on the Tokyo Stock Exchange and employs over 1,000 employees. Fuji Pharma's business model is to provide its customers with innovative and high-quality products that contribute to improving health and well-being. The company specializes in several business areas, including the development, manufacturing, and marketing of pharmaceutical products, production of OEM products for other companies, and manufacturing of dietary supplements and cosmetics. An important area for Fuji Pharma is the development and production of pharmaceuticals. The company ensures that its medications meet the highest requirements and international standards. This includes research and development of new products. The company has its own research department specializing in the development of medications that can be used in serious diseases such as cancer, diabetes, and cardiovascular diseases. In addition, Fuji Pharma is also involved in the production of OEM products for other companies. The company ensures the manufacture of medications and medical products for other pharmaceutical companies, meeting the highest quality standards and customer requirements. Fuji Pharma is proud to be a trusted partner for its customers and provides its services according to the requirements of its customers. In addition to these two divisions, Fuji Pharma also produces dietary supplements and cosmetics for the domestic and international markets. These products are designed for consumers who want to improve their health and well-being. The company places great emphasis on the development of natural and safe ingredients for its products and ensures the highest standards of quality and safety. Fuji Pharma has also specialized in the Japanese market for medical devices, particularly in the field of home respiratory devices. The company has developed a new generation of respiratory therapy devices that are safe and easy to use, providing better well-being and quality of life for patients with respiratory diseases. In addition to its business areas, Fuji Pharma also has various products in its portfolio that are known for their quality and effectiveness. One such product is "Efil," a medication used in the treatment of erectile dysfunction disorders. The medication is available in Japan and other Asian countries and has already been used by over 200,000 patients. Fuji Pharma continuously strives to improve its research and development activities and develop new innovative products and services for the healthcare industry. The company aims to bring its products and services to the international market and satisfy its customers in Japan and worldwide. Fuji Pharma Co is one of the most popular companies on Eulerpool.com.

Fuji Pharma Co SWOT Analysis

Strengths

Fuji Pharma Co Ltd enjoys several strengths in the pharmaceutical industry. These strengths include:

  • Strong reputation in the market
  • Wide range of high-quality products
  • Extensive distribution network
  • Strong financial position
  • Innovative research and development capabilities
  • Strong brand recognition

Weaknesses

Despite its strengths, Fuji Pharma Co Ltd also faces certain weaknesses that need to be addressed:

  • Dependency on a limited number of key products
  • Relatively low market share in certain segments
  • Limited international presence
  • Increasing competition from larger pharmaceutical companies
  • Lack of diversification

Opportunities

Fuji Pharma Co Ltd can leverage the following opportunities for growth and expansion:

  • Market expansion in emerging economies
  • Increasing demand for generic drugs
  • Growing healthcare expenditure worldwide
  • Potential partnerships and collaborations
  • Advancements in technology for drug development

Threats

It is crucial for Fuji Pharma Co Ltd to mitigate the following threats that may impact its business:

  • Stringent regulatory requirements
  • Fluctuating exchange rates
  • Patent expirations
  • Emergence of new competitors
  • Healthcare reforms
  • Political and economic instability in certain markets

Fuji Pharma Co historical P/E ratio, EBIT, and P/S ratio.

Fuji Pharma Co shares outstanding

The number of shares was Fuji Pharma Co in 2023 — This indicates how many shares 24.301 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fuji Pharma Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fuji Pharma Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fuji Pharma Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fuji Pharma Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Fuji Pharma Co Stock splits

In Fuji Pharma Co's history, there have been no stock splits.

Fuji Pharma Co dividend history and estimates

In 2023, Fuji Pharma Co paid a dividend amounting to 37 JPY. Dividend means that Fuji Pharma Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Fuji Pharma Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Fuji Pharma Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Fuji Pharma Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Fuji Pharma Co Dividend History

DateFuji Pharma Co Dividend
2027e38.85 undefined
2026e38.84 undefined
2025e38.86 undefined
2024e38.86 undefined
202337 undefined
202235 undefined
202129 undefined
202029 undefined
201929 undefined
201828 undefined
201724 undefined
201622.5 undefined
201522 undefined
201422 undefined
201320 undefined
201218.5 undefined
20111.5 undefined

Fuji Pharma Co dividend payout ratio

In 2023, Fuji Pharma Co had a payout ratio of 35.64%. The payout ratio indicates the percentage of the company's profits that Fuji Pharma Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Fuji Pharma Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Fuji Pharma Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Fuji Pharma Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Fuji Pharma Co Payout Ratio History

DateFuji Pharma Co Payout ratio
2027e33.51 %
2026e34.04 %
2025e33.42 %
2024e33.07 %
202335.64 %
202231.54 %
202132.04 %
202043.34 %
201929.89 %
201824.85 %
201721.76 %
201631.78 %
201531.99 %
201431.76 %
201327.08 %
201237.79 %
20111.77 %
201035.64 %
200935.64 %
200835.64 %
200735.64 %
200635.64 %
200535.64 %
200435.64 %
Unfortunately, there are currently no price targets and forecasts available for Fuji Pharma Co.

Fuji Pharma Co list of shareholders

%
Name
Stocks
Change
Date
5.11 % Arai (Noriko)1,240,00009/30/2023
5.02 % Lotus Japan Holdings Co Ltd1,219,00009/30/2023
4.12 % Yamhill Sciences Co., Ltd.1,000,00009/30/2023
2.34 % Fidelity Management & Research Company LLC568,000-55,0009/30/2023
17.73 % YK FJP4,307,000-25,0009/30/2023
12.57 % Imai (Hirofumi)3,052,00009/30/2023
1.92 % Nomura Asset Management Co., Ltd.466,4952,9003/31/2024
1.84 % Imai (Michiko)446,00009/30/2023
1.73 % The Vanguard Group, Inc.419,31003/31/2024
1.69 % Dimensional Fund Advisors, L.P.410,0004,6003/31/2024
1
2
3
4
...
5

Fuji Pharma Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Mithra Pharmaceuticals Stock
Mithra Pharmaceuticals
SupplierCustomer0,450,080,790,760,670,62
Mochida Pharmaceutical Stock
Mochida Pharmaceutical
SupplierCustomer0,410,680,76-0,04-0,110,65
PALTAC Stock
PALTAC
SupplierCustomer0,320,470,200,090,770,78
Medical Ikkou Group Stock
Medical Ikkou Group
SupplierCustomer0,270,11-0,390,370,73-
Kidswell Bio Stock
Kidswell Bio
SupplierCustomer0,240,530,240,480,730,45
Suzuken Stock
Suzuken
SupplierCustomer0,130,720,28-0,56-0,650,53
Toho Stock
Toho
SupplierCustomer0,110,79-0,68-0,70-0,350,31
Mitsubishi UFJ Financial Group Stock
Mitsubishi UFJ Financial Group
SupplierCustomer0,04-0,24-0,42-0,64-0,77-0,67
Mitsui & Co Stock
Mitsui & Co
SupplierCustomer-0,020,21-0,51-0,74-0,83-0,70
M3 Stock
M3
SupplierCustomer-0,140,120,490,690,950,73
1
2

Most common questions regarding Fuji Pharma Co

What values and corporate philosophy does Fuji Pharma Co represent?

Fuji Pharma Co Ltd represents values and a corporate philosophy centered around innovation, commitment to quality, and customer satisfaction. As a renowned pharmaceutical company, Fuji Pharma prioritizes research and development to deliver cutting-edge treatments and healthcare solutions. With a focus on improving global health, the company operates with integrity, ethical business practices, and compliance with regulatory standards. Fuji Pharma Co Ltd aims to contribute to society by providing reliable and safe pharmaceutical products that enhance the health and well-being of individuals worldwide.

In which countries and regions is Fuji Pharma Co primarily present?

Fuji Pharma Co Ltd is primarily present in Japan.

What significant milestones has the company Fuji Pharma Co achieved?

Fuji Pharma Co Ltd has achieved significant milestones in its operations. The company has successfully expanded its product portfolio and gained recognition in the pharmaceutical industry. Through innovative research and development efforts, Fuji Pharma Co Ltd has introduced several breakthrough drugs and treatment options that have improved patients' lives. The company has also established valuable partnerships and collaborations with renowned global players, enhancing its market presence. Fuji Pharma Co Ltd's commitment to quality and innovation has earned it widespread acclaim and customer trust. As the company continues to excel in its journey, it remains dedicated to delivering cutting-edge pharmaceutical solutions that cater to diverse healthcare needs.

What is the history and background of the company Fuji Pharma Co?

Fuji Pharma Co Ltd, a renowned pharmaceutical company, has a rich history and robust background. Established in [year], it has consistently made notable contributions to the healthcare industry. With a strong focus on research and development, Fuji Pharma specializes in the development, manufacturing, and distribution of innovative pharmaceutical products. The company is committed to improving people's quality of life by offering a diverse range of high-quality medications and healthcare solutions. Fuji Pharma's dedication to excellence, customer satisfaction, and cutting-edge technology has positioned it as a leader in the industry. Their unwavering commitment to delivering effective healthcare solutions has earned them a stellar reputation among both healthcare professionals and patients alike.

Who are the main competitors of Fuji Pharma Co in the market?

The main competitors of Fuji Pharma Co Ltd in the market include companies such as Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., and Eisai Co., Ltd. These companies operate in the pharmaceutical industry and offer a range of products and services that compete with Fuji Pharma. Fuji Pharma Co Ltd is a reputable player in the market and faces competition from these well-established competitors in delivering innovative pharmaceutical solutions to customers.

In which industries is Fuji Pharma Co primarily active?

Fuji Pharma Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of Fuji Pharma Co?

The business model of Fuji Pharma Co Ltd revolves around the pharmaceutical industry. Fuji Pharma Co Ltd is primarily engaged in the manufacturing and sales of various pharmaceutical products. The company focuses on developing and commercializing innovative drugs and medical devices, aiming to contribute to the improvement of global health. With a strong emphasis on research and development, Fuji Pharma Co Ltd aims to provide effective and safe medications to meet the healthcare needs of people worldwide. As a prominent player in the pharmaceutical sector, Fuji Pharma Co Ltd strives to maintain its position through continuous innovation, strategic collaborations, and customer-centric approaches.

What is the P/E ratio of Fuji Pharma Co 2024?

The Fuji Pharma Co P/E ratio is 6.15.

What is the P/S ratio of Fuji Pharma Co 2024?

The Fuji Pharma Co P/S ratio is 0.74.

What is the AlleAktien quality score of Fuji Pharma Co?

The AlleAktien quality score for Fuji Pharma Co is 5/10.

What is the revenue of Fuji Pharma Co 2024?

The expected Fuji Pharma Co revenue is 47.96 B JPY.

How high is the profit of Fuji Pharma Co 2024?

The expected Fuji Pharma Co profit is 5.8 B JPY.

What is the business model of Fuji Pharma Co

Fuji Pharma Co Ltd is a Japanese company that was founded in 1950. The company is primarily engaged in the manufacture and sale of pharmaceuticals, medical devices, and cosmetics. They have several business areas to meet the various needs of consumers.

What is the Fuji Pharma Co dividend?

Fuji Pharma Co pays a dividend of 35 JPY distributed over payouts per year.

How often does Fuji Pharma Co pay dividends?

The dividend cannot currently be calculated for Fuji Pharma Co or the company does not pay out a dividend.

What is the Fuji Pharma Co ISIN?

The ISIN of Fuji Pharma Co is JP3816200004.

What is the Fuji Pharma Co WKN?

The WKN of Fuji Pharma Co is 938283.

What is the Fuji Pharma Co ticker?

The ticker of Fuji Pharma Co is 4554.T.

How much dividend does Fuji Pharma Co pay?

Over the past 12 months, Fuji Pharma Co paid a dividend of 37 JPY . This corresponds to a dividend yield of about 2.52 %. For the coming 12 months, Fuji Pharma Co is expected to pay a dividend of 38.86 JPY.

What is the dividend yield of Fuji Pharma Co?

The current dividend yield of Fuji Pharma Co is 2.52 %.

When does Fuji Pharma Co pay dividends?

Fuji Pharma Co pays a quarterly dividend. This is distributed in the months of April, October, April, October.

How secure is the dividend of Fuji Pharma Co?

Fuji Pharma Co paid dividends every year for the past 17 years.

What is the dividend of Fuji Pharma Co?

For the upcoming 12 months, dividends amounting to 38.86 JPY are expected. This corresponds to a dividend yield of 2.65 %.

In which sector is Fuji Pharma Co located?

Fuji Pharma Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fuji Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fuji Pharma Co from 12/1/2024 amounting to 22.5 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Fuji Pharma Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Fuji Pharma Co in the year 2023?

In the year 2023, Fuji Pharma Co distributed 35 JPY as dividends.

In which currency does Fuji Pharma Co pay out the dividend?

The dividends of Fuji Pharma Co are distributed in JPY.

All fundamentals about Fuji Pharma Co

Our stock analysis for Fuji Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fuji Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.